JAMA Oncology

JAMA Oncology JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed publications.

Systematic review and meta-analysis evaluated the frequency of second primary malignant neoplasms (SPMs) in patients rec...
06/19/2026

Systematic review and meta-analysis evaluated the frequency of second primary malignant neoplasms (SPMs) in patients receiving T-cell–engaging bispecific antibodies for B-cell non-Hodgkin lymphoma or multiple myeloma.

Across 20 studies including 2551 adults (median follow-up, 17.4 months), the pooled estimated frequency of reported SPMs was 3.5%, while frequencies of SPMs leading to treatment discontinuation and death were 2.2% and 1.4%, respectively. Most SPMs were nonmelanoma skin cancers or hematologic malignant neoplasms, and frequency did not differ significantly by underlying disease, follow-up duration, or baseline clinical features.

Heterogeneous definitions and inconsistent study reporting complicated risk estimation, highlighting the need for strengthened, standardized long-term surveillance of T-cell–engaging bispecific antibody therapies.

https://ja.ma/4ewzWrD

A multicenter phase 1/2 nonrandomized clinical trial evaluated the feasibility and safety of single-fraction stereotacti...
06/19/2026

A multicenter phase 1/2 nonrandomized clinical trial evaluated the feasibility and safety of single-fraction stereotactic body radiotherapy (SBRT; 19 Gy) in men with localized .

Among patients with low- or intermediate-risk disease, the estimated 3-year biochemical relapse-free survival (bRFS) was 92.9%, meeting the study’s predefined efficacy threshold. At 3 years, grade 2 genitourinary adverse events were observed in

Sequential radiotherapy and immunotherapy ( ) provided longer overall survival than concurrent iRT for newly diagnosed a...
06/16/2026

Sequential radiotherapy and immunotherapy ( ) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy.

https://ja.ma/4vJ3tW2

This JAMA Oncology Patient Page discusses benefits and risks of local consolidative therapy for metastatic and which p...
06/14/2026

This JAMA Oncology Patient Page discusses benefits and risks of local consolidative therapy for metastatic and which patients might be considered for this treatment.

https://ja.ma/4vQ8fRK

A 58-year-old woman with with multiple prior courses of systemic treatments presented with hypotension, hypoxia, signi...
06/13/2026

A 58-year-old woman with with multiple prior courses of systemic treatments presented with hypotension, hypoxia, significant polyuria, and polydipsia. Mild thickening of the pituitary stalk was seen, while no discrete sellar or suprasellar masses were noted.

✍️ What is your diagnosis? Take the JAMA Oncology Clinical Challenge: https://ja.ma/4xsBGuI

Magnetic resonance imaging ( ) is routinely used in prostate cancer diagnosis, but there is uncertainty about its optima...
06/12/2026

Magnetic resonance imaging ( ) is routinely used in prostate cancer diagnosis, but there is uncertainty about its optimal use in population-level screening.

This Special Communication provides consensus recommendations on the acquisition, interpretation, and reporting of prostate MRI for cancer screening. https://ja.ma/4v1W1Fn

In a phase 1/2 nonrandomized clinical trial, patients with low-risk gestational trophoblastic tumors (GTT) received firs...
06/11/2026

In a phase 1/2 nonrandomized clinical trial, patients with low-risk gestational trophoblastic tumors (GTT) received first-line therapy with a combination of avelumab and methotrexate.

Among patients assessable for efficacy, 96.2% achieved normalization of human chorionic gonadotropin (hCG) and completed treatment without relapse at a median 41 months’ follow-up. The safety profile was manageable, with grade 2 or higher immune-related adverse events occurring in 22%, all but one of which resolved fully.

Among patients desiring fertility, 93% conceived after treatment, and the miscarriage rate was consistent with historical experience. These findings indicate that avelumab plus methotrexate may represent an effective first-line strategy for low-risk GTT, potentially reducing methotrexate resistance and preserving fertility.

https://ja.ma/3S05nmC

Sequential radiotherapy and immunotherapy ( ) provided longer overall survival than concurrent iRT for newly diagnosed a...
06/09/2026

Sequential radiotherapy and immunotherapy ( ) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy.

https://ja.ma/4oqQgyD

This JAMA Oncology Patient Page discusses benefits and risks of local consolidative therapy for metastatic and which p...
06/09/2026

This JAMA Oncology Patient Page discusses benefits and risks of local consolidative therapy for metastatic and which patients might be considered for this treatment.

https://ja.ma/4v1gOJp

In a population-based analysis from Texas, early age–onset colore**al cancer ( ), defined as diagnosis at age
06/06/2026

In a population-based analysis from Texas, early age–onset colore**al cancer ( ), defined as diagnosis at age

Address

330 N Wabash Avenue
Chicago, IL
60611

Telephone

+13126707827

Website

Alerts

Be the first to know and let us send you an email when JAMA Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category